{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:12:28Z","timestamp":1790741548389,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-56096-2","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T04:12:57Z","timestamp":1737000777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Lerociclib plus fulvestrant in patients with HR+\/HER2\u2212 locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6827-2268","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-386X","authenticated-orcid":false,"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changping","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-5780","authenticated-orcid":false,"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-0842","authenticated-orcid":false,"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"56096_CR1","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1002\/cncr.32832","volume":"126","author":"BH Xu","year":"2020","unstructured":"Xu, B. H. et al. Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer 126, 3867\u20133882 (2020).","journal-title":"Cancer"},{"key":"56096_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","volume":"2","author":"RS Zheng","year":"2022","unstructured":"Zheng, R. S. et al. Cancer incidence and mortality in China, 2016. J. Natl. Cancer Cent. 2, 1\u20139 (2022).","journal-title":"J. Natl. Cancer Cent."},{"key":"56096_CR3","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","volume":"383","author":"HJ Burstein","year":"2020","unstructured":"Burstein, H. J. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N. Engl. J. Med. 383, 2557\u20132570 (2020).","journal-title":"N. Engl. J. Med."},{"key":"56096_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.4161\/cc.6.6.3988","volume":"6","author":"EE Bosco","year":"2007","unstructured":"Bosco, E. E. & Knudsen, E. S. RB in breast cancer: At the crossroads of tumorigenesis and treatment. Cell Cycle 6, 667\u2013671 (2007).","journal-title":"Cell Cycle"},{"key":"56096_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"56096_CR6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1080\/03007995.2017.1348344","volume":"33","author":"B Bilgin","year":"2017","unstructured":"Bilgin, B., Sendur, M. A. N., Dede, D. S., Akinci, M. B. & Yal\u00e7in, B. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer. Curr. Med. Res. Opin. 33, 1559\u20131569 (2017).","journal-title":"Curr. Med. Res. Opin."},{"key":"56096_CR7","doi-asserted-by":"publisher","first-page":"2875-+","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge, G. W. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875-+ (2017).","journal-title":"J. Clin. Oncol."},{"key":"56096_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge, G. W. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2 a randomized clinical trial. JAMA Oncol. 6, 116\u2013124 (2020).","journal-title":"JAMA Oncol."},{"key":"56096_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1758835920963925","volume":"12","author":"QY Zhang","year":"2020","unstructured":"Zhang, Q. Y. et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2-advanced breast cancer: the multinational randomized phase III study. Ther. Adv. Med. Oncol. 12, 14 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"56096_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner, N. C. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209\u2013219 (2015).","journal-title":"N. Engl. J. Med."},{"key":"56096_CR11","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926\u20131936 (2018).","journal-title":"N. Engl. J. Med."},{"key":"56096_CR12","doi-asserted-by":"publisher","first-page":"2465-+","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36, 2465-+ (2018).","journal-title":"J. Clin. Oncol."},{"key":"56096_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon, D. J. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl. J. Med. 382, 514\u2013524 (2020).","journal-title":"N. Engl. J. Med."},{"key":"56096_CR14","doi-asserted-by":"publisher","first-page":"1904-+","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"BH Xu","year":"2021","unstructured":"Xu, B. H. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat. Med. 27, 1904-+ (2021).","journal-title":"Nat. Med."},{"key":"56096_CR15","doi-asserted-by":"publisher","first-page":"S642","DOI":"10.1016\/j.annonc.2022.07.268","volume":"33","author":"P Zhang","year":"2022","unstructured":"Zhang, P. et al. Dalpiciclib plus fulvestrant in HR+\/HER2-advanced breast cancer (ABC): updated analysis from the phase III DAWNA-1 trial. Ann. Oncol. 33, S642\u2013S643 (2022).","journal-title":"Ann. Oncol."},{"key":"56096_CR16","doi-asserted-by":"publisher","first-page":"42343","DOI":"10.18632\/oncotarget.16216","volume":"8","author":"JE Bisi","year":"2017","unstructured":"Bisi, J. E. et al. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4\/6 for use as an oral antineoplastic in patients with CDK4\/6 sensitive tumors. Oncotarget 8, 42343\u201342358 (2017).","journal-title":"Oncotarget"},{"key":"56096_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1158\/1541-7786.MCR-17-0028","volume":"15","author":"JP Stice","year":"2017","unstructured":"Stice, J. P. et al. CDK4\/6 therapeutic intervention and viable alternative to taxanes in CRPC. Mol. Cancer Res. 15, 660\u2013669 (2017).","journal-title":"Mol. Cancer Res."},{"key":"56096_CR18","doi-asserted-by":"publisher","first-page":"S380","DOI":"10.1016\/j.annonc.2020.08.436","volume":"31","author":"I Bulat","year":"2020","unstructured":"Bulat, I. et al. Lerociclib (G1T38), a continuously dosed oral CDK4\/6 inhibitor, with fulvestrant in HR+\/HER2-advanced breast cancer patients: Updated phase II results and dose selection. Ann. Oncol. 31, S380\u2013S380 (2020).","journal-title":"Ann. Oncol."},{"key":"56096_CR19","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","volume":"25","author":"F Cardoso","year":"2014","unstructured":"Cardoso, F. et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann. Oncol. 25, 1871\u20131888 (2014).","journal-title":"Ann. Oncol."},{"key":"56096_CR20","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","volume":"28","author":"A Di Leo","year":"2010","unstructured":"Di Leo, A. et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 28, 4594\u20134600 (2010).","journal-title":"J. Clin. Oncol."},{"key":"56096_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004","volume":"40","author":"K Kalinsky","year":"2022","unstructured":"Kalinsky, K. et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4\/6 inhibition (CDK 4\/6i) in patients (pts) with unresectable or hormone receptor positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. J. Clin. Oncol. 40, 1 (2022).","journal-title":"J. Clin. Oncol."},{"key":"56096_CR22","doi-asserted-by":"publisher","first-page":"LBA1000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA1000","volume":"41","author":"GS Sonke","year":"2023","unstructured":"Sonke, G. S. et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4\/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). J. Clin. Oncol. 41, LBA1000 (2023).","journal-title":"J. Clin. Oncol."},{"key":"56096_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0121-y","volume":"5","author":"A Marra","year":"2019","unstructured":"Marra, A. & Curigliano, G. Are all cyclin-dependent kinases 4\/6 inhibitors created equal? NPJ breast cancer 5, 27 (2019).","journal-title":"NPJ breast cancer"},{"key":"56096_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"56096_CR25","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (National Institutes of Health, National Cancer Institute US Department of Health and Human Services, 2017)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56096-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T04:13:01Z","timestamp":1737000781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56096-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56096"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56096-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"28 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: B.X. discloses receiving advisory fees from Novartis and AstraZeneca. D.Z. and T.L. were employees of Genor Biopharma at the time of the study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"716"}}